5 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
Follow Common Variable Immunodeficiency: new trials by email Literature Review of Common Variable Immunodeficiency trials Research Report on Common Variable Immunodeficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease Abatacept, Placebo - Interstitial Lung Disease, Common Variable Immunodeficiency | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 38 | 2021-07-14 | 2026-07-22 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L - Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 354 | 2015-11-19 | 2026-10-26 |
Autoimmune Diseases (2) · Immune System Diseases (2) · Lymphoproliferative Disorders (2) · Opportunistic Infections (2) · T cell immunodeficiency primary (2) · Agammaglobulinemia (1) · DiGeorge Syndrome (1) · Granulomatous Disease, Chronic (1) · Hyper-IgM Immunodeficiency Syndrome (1) · Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome (1) · Intestinal Diseases (1) · Lung Diseases, Interstitial (1) · Multiple Myeloma (1) · Severe Combined Immunodeficiency (1)
Immunologic Deficiency Syndromes (5) · Hemic and Lymphatic Diseases (4) · Lymphatic Diseases (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Infections (2) · 22q11 Deletion Syndrome (1) · Abnormalities, Multiple (1) · Cardiovascular Abnormalities (1) · Chromosome Disorders (1) · Chronic Disease (1) · Congenital Abnormalities (1)
Abatacept (1) · Alemtuzumab (1) · Busulfan (1) · Cyclophosphamide (1) · Hizentra (1) · Mycophenolic Acid (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · fludarabine (1)
National Cancer Institute (NCI) (2) · Children's Hospital Medical Center, Cincinnati (1) · Memorial Sloan Kettering Cancer Center (1) · Paul Szabolcs (1)
United States (5)
Dimana Dimitrova, M.D. (1) · Michael Jordan (1) · Paul Szabolcs, MD (1) · Sung-Yun Pai, M.D. (1) · Zainab Shahid, MBBS (1)